SCHEMBL4120523

SCHEMBL4120523

CCN(CC)CCN(CCNC(=S)Nc1ccc(N(CC)CC)cc1)C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.53
▸ MEN1 O00255 7/20 0.51
▸ KMT2A Q03164 7/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ LMNA P02545 3/20 0.51
▸ HTT P42858 2/20 0.51
▸ CDK1 P06493 1/20 0.48
▸ NPC1 O15118 4/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ ALDH1A1 P00352 6/20 0.44
▸ MAPT P10636 5/20 0.44
▸ GAA P10253 4/20 0.44
▸ MAPK1 P28482 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ THRB P10828 2/20 0.44
▸ TDP1 Q9NUW8 3/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ NOX1 Q9Y5S8 1/20 0.42
▸ MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107405 0.90 MCHR1 (0.60) MCHR1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL4107368 0.85 EPHX2 (0.47) MCHR1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4114249 0.85 MCHR1 (0.59) MCHR1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4118376 0.84 MCHR1 (0.66) MCHR1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5706056 0.83 MCHR1 (0.48) MCHR1MEN1KMT2ALMNANPC1
SCHEMBL4118355 0.82 MEN1 (0.55) MCHR1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL4115328 0.81 MCHR1 (0.61) MCHR1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL4119645 0.80 MCHR1 (0.60) MCHR1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL4124390 0.80 MCHR1 (0.54) MCHR1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4113680 0.78 MCHR1 (0.54) MCHR1MEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS MCHR1 4128/4885MEN1 4167/4885KMT2A 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback